SH3TC2

Across TCGA pan-cancer cohorts, SH3TC2 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated SH3TC2 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher SH3TC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SH3TC2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, LIHC, and LUSC are the cancer types where SH3TC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.117	0.703	<.001	36	view →
LIHC	OS	Median	III,IV	0.093	0.649	<.001	24	view →
LUSC	DFS	Median	II,III,IV	0.079	0.750	<.001	15	view →
GBM	OS	Median	All	0.094	0.415	.001	12	view →
COAD	OS	Median	III,IV	0.082	0.792	<.001	12	view →
LUAD	OS	Median	All	0.609	0.817	.011	8	view →
LAML	DFS	Median	All	0.140	0.582	.020	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	II,III,IV	0.884	0.434	.030	4	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

SH3TC2–ESCA (OS)

Open the ESCA breakdown →